WCN26-6413 PERIPHERAL IMMUNE CELL RESPONSES TO TOCILIZUMAB TREATMENT IN PLASMA CELL-TYPE CASTLEMAN DISEASE WITH RENAL INVOLVEMENT USING SINGLE-CELL RNA SEQUENCING

Read full text Summarise with VIRAT
Authors: Yu Watanabe, Eri Koshi-Ito, Chikao Onogi, Akihito Tanaka, Kazuhiro Furuhashi, Hiroshi I. Suzuki, Shoichi Maruyama
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Plasma cell-type Castleman disease (PCD) is a rare lymphoproliferative disorder characterized by IL-6 overproduction, systemic inflammation, and potential renal involvement. Tocilizumab, an IL-6 receptor antagonist, effectively improves clinical symptoms, but molecular mechanisms underlying therapeutic responses remain unclear. We performed single-cell RNA sequencing (scRNA-seq) of peripheral blood mononuclear cells (PBMCs) to elucidate immune cell gene expression changes following tocilizumab treatment in PCD with renal involvement.

Fields of Study & Subjects

Autoimmune and Inflammatory Disorders Research Viral-associated cancers and disorders Lymphoma Diagnosis and Treatment

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
103998–103998
Publication date
25 March 2026
Language
EN